Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine
carboxamide family that is currently approved as adjunctive therapy and monotherapy for …

This article discusses seven newly available antiepileptic drugs (AEDs) and agents in phase
III development. Lacosamide, licensed as an adjunctive treatment for partial-onset seizures …

Background and Objectives To evaluate long-term efficacy (percent seizure frequency
reduction and responder rates), safety, and tolerability of adjunctive cenobamate (CNB) in …

This study aimed at evaluating the effects of eslicarbazepine, carbamazepine (CBZ),
oxcarbazepine (OXC) and lacosamide (LCM) on the fast and slow inactivated states of …

Purpose: To evaluate safety, tolerability, and seizure outcome data during long‐term
treatment with once‐daily adjunctive perampanel (up to 12 mg/day) in patients with …

Objective We determined retention on open‐label cenobamate therapy in the clinical
development program to assess the long‐term efficacy and tolerability of adjunctive …

Objective We assessed the efficacy and safety of once‐daily eslicarbazepine acetate in
comparison with twice‐daily (BID) controlled‐release carbamazepine (carbamazepine‐CR) …

In human epilepsy, pharmacoresistance to antiepileptic drug therapy is a major problem
affecting a substantial fraction of patients. Many of the currently available antiepileptic drugs …

Objectives To report pooled safety/tolerability and seizure outcome data from adults with
uncontrolled partial‐onset (focal) seizures (POS) receiving adjunctive brivaracetam (BRV) …

Objectives Evaluate interim long‐term tolerability, safety and efficacy of adjunctive
perampanel, a novel α‐amino‐3‐hydroxy‐5‐methyl‐5‐isoxazolepropionic acid (AMPA) …